InvestorsHub Logo
Followers 4
Posts 479
Boards Moderated 0
Alias Born 01/03/2015

Re: None

Sunday, 12/24/2017 11:16:48 AM

Sunday, December 24, 2017 11:16:48 AM

Post# of 403036
As there are currently no approved drugs for prevention of severe OM in patients receiving chemoradiation treatment of HNC, management opinion is that Brilacidin-OM has the potential to rapidly assume a lead position after market introduction. This perspective is shared by multiple Pharma companies, potential partners the Company currently is in active discussions with, equally interested in the continued development and eventual market introduction of Brilacidin-OM worldwide.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News